Aerovate Therapeutics/AVTE

$23.83

3.24%
-
1D1W1MYTD1YMAX

About Aerovate Therapeutics

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary diseases. Its AV-101, a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. It provides Imatinib, marketed as Gleevec tablets, is developed for the treatment of multiple cancers. Oral imatinib also demonstrates statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in pulmonary arterial hypertension (PAH) patients. PAH is an orphan disease characterized by increased pressure in the pulmonary arteries, vessels responsible for carrying deoxygenated blood from the heart to the lungs.

Ticker

AVTE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Benjamin Dake

Employees

43

Headquarters

Waltham, United States

AVTE Metrics

BasicAdvanced
$659.35M
Market cap
-
P/E ratio
-$2.74
EPS
-
Beta
-
Dividend rate

What the Analysts think about AVTE

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
35.67% upside
High $48.00
Low $21.00
$23.83
Current price
$32.33
Average price target

AVTE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-19.5M
2.63%
Profit margin
0%
-

AVTE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.66%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.61
-$0.67
-$0.76
-$0.71
-
Expected
-$0.62
-$0.60
-$0.70
-$0.69
-$0.71
Surprise
-1.26%
11.67%
9.2%
2.66%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aerovate Therapeutics stock

Buy or sell Aerovate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing